Liraglutids glukose- og vægtreducerende effekt ved behandling af type 2-diabetes

Ida Elisabeth Irene Penninga, Kristine Færch, Thomas Almdal

Abstract

Treatment with glucagon-like peptide-1 analogues including liraglutide is a new treatment option for patients with type 2 diabetes. Treatment with liraglutide decreases HbA1c by 1-2%, and additionally liraglutide has a reducing effect on weight, lipids and blood pressure. Most adverse events are related to the gastrointestinal system and most often they disappear within a few weeks. The risk of major hypoglycaemic episodes is minimal. Long term data on treatment and adverse events with liraglutide are still lacking.
Bidragets oversatte titelWeight reducing and glucose reducing effects of liraglutide treatment for patients with type 2 diabetes
OriginalsprogDansk
TidsskriftUgeskrift for Laeger
Vol/bind173
Udgave nummer26
Sider (fra-til)1863-9
Antal sider7
ISSN0041-5782
StatusUdgivet - 27 jun. 2011

Emneord

  • Blood Glucose
  • Blood Pressure
  • Body Weight
  • Diabetes Mellitus, Type 2
  • Drug Therapy, Combination
  • Glucagon-Like Peptide 1
  • Hemoglobin A, Glycosylated
  • Humans
  • Hypoglycemic Agents
  • Lipids
  • Treatment Outcome

Fingeraftryk

Dyk ned i forskningsemnerne om 'Liraglutids glukose- og vægtreducerende effekt ved behandling af type 2-diabetes'. Sammen danner de et unikt fingeraftryk.

Citationsformater